Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:GERN NASDAQ:IRWD NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$231.03-0.1%$214.12$163.81▼$244.81$408.50B0.516.77 million shs4.61 million shsGERNGeron$1.39+0.7%$1.35$1.09▼$4.50$880.46M0.576.86 million shs7.81 million shsIRWDIronwood Pharmaceuticals$1.77+12.0%$1.23$0.53▼$5.13$256.65M0.31.31 million shs1.73 million shsZBIOZenas BioPharma$27.76+7.2%$18.64$5.83▼$28.72$1.09BN/A317,793 shs832,424 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.10%-2.51%+9.77%+20.13%+18.68%GERNGeron+0.72%+0.72%+2.21%+5.30%-67.06%IRWDIronwood Pharmaceuticals+12.03%+9.94%+59.46%+135.28%-57.96%ZBIOZenas BioPharma+7.18%+32.51%+27.11%+148.30%+2,775,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$231.03-0.1%$214.12$163.81▼$244.81$408.50B0.516.77 million shs4.61 million shsGERNGeron$1.39+0.7%$1.35$1.09▼$4.50$880.46M0.576.86 million shs7.81 million shsIRWDIronwood Pharmaceuticals$1.77+12.0%$1.23$0.53▼$5.13$256.65M0.31.31 million shs1.73 million shsZBIOZenas BioPharma$27.76+7.2%$18.64$5.83▼$28.72$1.09BN/A317,793 shs832,424 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.10%-2.51%+9.77%+20.13%+18.68%GERNGeron+0.72%+0.72%+2.21%+5.30%-67.06%IRWDIronwood Pharmaceuticals+12.03%+9.94%+59.46%+135.28%-57.96%ZBIOZenas BioPharma+7.18%+32.51%+27.11%+148.30%+2,775,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.79Moderate Buy$231.900.38% UpsideGERNGeron 2.13Hold$3.79172.35% UpsideIRWDIronwood Pharmaceuticals 2.25Hold$4.94179.10% UpsideZBIOZenas BioPharma 2.50Moderate Buy$38.3338.09% UpsideCurrent Analyst Ratings BreakdownLatest IRWD, ABBV, ZBIO, and GERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$284.0010/9/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$250.0010/9/2025ZBIOZenas BioPharmaWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $40.0010/9/2025ZBIOZenas BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.0010/8/2025ABBVAbbVieWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025GERNGeronWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IRWDIronwood PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ZBIOZenas BioPharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025IRWDIronwood PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/3/2025ABBVAbbVieUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$251.0010/3/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$220.00 ➝ $251.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B7.24$14.91 per share15.49$1.90 per share121.59GERNGeron$76.99M11.52N/AN/A$0.46 per share3.02IRWDIronwood Pharmaceuticals$308.52M0.93$0.06 per share31.94($1.88) per share-0.94ZBIOZenas BioPharma$15M77.93N/AN/A$7.48 per share3.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.10110.0116.531.356.45%699.66%13.64%10/31/2025 (Estimated)GERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)IRWDIronwood Pharmaceuticals$880K-$0.05N/A7.08N/A-2.25%-2.46%2.19%11/6/2025 (Estimated)ZBIOZenas BioPharma-$156.99M-$3.55N/A∞N/AN/A-59.21%-50.56%11/11/2025 (Estimated)Latest IRWD, ABBV, ZBIO, and GERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025GERNGeron-$0.03N/AN/AN/A$55.24 millionN/A11/6/2025Q3 2025IRWDIronwood Pharmaceuticals$0.08N/AN/AN/A$74.22 millionN/A10/31/2025Q3 2025ABBVAbbVie$3.26N/AN/AN/A$15.58 billionN/A8/12/2025Q2 2025ZBIOZenas BioPharma-$1.02-$1.25-$0.23-$1.25$5.00 millionN/A8/7/2025Q2 2025IRWDIronwood Pharmaceuticals-$0.02$0.14+$0.16$0.14$62.02 million$85.24 million8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 million7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.562.84%N/A312.38%53 YearsGERNGeronN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/AZBIOZenas BioPharma$0.050.17%N/AN/A N/ALatest IRWD, ABBV, ZBIO, and GERN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/5/2025ABBVAbbViequarterly$1.643.08%10/15/202510/15/202511/14/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.61GERNGeron0.467.876.79IRWDIronwood PharmaceuticalsN/A0.820.82ZBIOZenas BioPharmaN/A5.235.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%GERNGeron73.71%IRWDIronwood PharmaceuticalsN/AZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%GERNGeron7.42%IRWDIronwood Pharmaceuticals12.70%ZBIOZenas BioPharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableGERNGeron70638.02 million590.68 millionOptionableIRWDIronwood Pharmaceuticals220162.43 million141.81 millionOptionableZBIOZenas BioPharmaN/A42.11 million35.16 millionN/AIRWD, ABBV, ZBIO, and GERN HeadlinesRecent News About These CompaniesZenas BioPharma: Strategic Licensing and Clinical Advancements Justify Buy Rating1 hour ago | tipranks.comInsider Buying: Zenas BioPharma (NASDAQ:ZBIO) Insider Acquires 36,928 Shares of Stock2 hours ago | insidertrades.comHC Wainwright & Co. Reiterates Zenas BioPharma (ZBIO) Buy RecommendationOctober 9 at 2:52 PM | msn.comZenas BioPharma rises after Wedbush raises price targetOctober 9 at 2:52 PM | msn.comZenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare DealOctober 9 at 8:19 AM | seekingalpha.comStrategic Expansion and Financial Strength Bolster Zenas BioPharma’s Growth Potential: Buy Rating ReaffirmedOctober 9 at 6:51 AM | tipranks.comZenas BioPharma (Nasdaq:ZBIO) Secures License for Three Autoimmune Candidates Including OrelabrutinibOctober 9 at 4:48 AM | kalkinemedia.comKZenas Biopharma stock soars after securing rights to MS drug candidateOctober 8 at 6:46 PM | za.investing.comZenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase ...October 8 at 6:46 PM | finance.yahoo.comZenas Biopharma Acquires Rights to Three Autoimmune Drug Candidates from InnoCareOctober 8 at 6:46 PM | msn.comZenas climbs on licensing deal with InnoCareOctober 8 at 6:46 PM | msn.comZenas BioPharma (NASDAQ:ZBIO) Receives "Sell (D-)" Rating from Weiss RatingsOctober 8 at 1:06 PM | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Shares Gap Up - What's Next?October 8 at 11:26 AM | marketbeat.comZenas BioPharma Secures Licensing Deal with InnoCareOctober 8 at 6:31 AM | tipranks.comZenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drugOctober 8 at 6:04 AM | reuters.comZenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple SclerosisOctober 8 at 5:00 AM | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) Trading 8.9% Higher - Here's What HappenedOctober 6, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Shares Down 5.3% - What's Next?October 2, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Shares Up 5% - Should You Buy?September 30, 2025 | marketbeat.comBullish Zenas BioPharma Insiders Loaded Up On US$1.11m Of StockSeptember 30, 2025 | finance.yahoo.comGoldman Sachs Group Inc. Cuts Stake in Zenas BioPharma, Inc. $ZBIOSeptember 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 20253 Exceptional Stocks to Build Long-Term WealthBy Chris Markoch | October 6, 2025Why AbbVie and Johnson & Johnson Could Outperform PfizerBy Chris Markoch | October 8, 2025IRWD, ABBV, ZBIO, and GERN Company DescriptionsAbbVie NYSE:ABBV$231.03 -0.21 (-0.09%) Closing price 10/9/2025 03:59 PM EasternExtended Trading$231.66 +0.63 (+0.27%) As of 07:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Geron NASDAQ:GERN$1.39 +0.01 (+0.72%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$1.42 +0.03 (+2.16%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Ironwood Pharmaceuticals NASDAQ:IRWD$1.77 +0.19 (+12.03%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$1.80 +0.03 (+1.98%) As of 07:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Zenas BioPharma NASDAQ:ZBIO$27.76 +1.86 (+7.18%) As of 10/9/2025 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
